Current Report Filing (8-k)
07 Giugno 2022 - 11:28PM
Edgar (US Regulatory)
0001560293falseCA
0001560293
2022-06-07
2022-06-07
0001560293
2022-03-31
0001560293
2021-12-31
0001560293
2022-01-01
2022-03-31
0001560293
2021-01-01
2021-03-31
0001560293
us-gaap:CommonStockMember
2022-06-07
2022-06-07
0001560293
tnon:SeriesAConvertiblePreferredStockMember
2022-03-31
0001560293
tnon:SeriesBConvertiblePreferredStockMember
2022-03-31
0001560293
tnon:SeriesAConvertiblePreferredStockMember
2021-12-31
0001560293
tnon:SeriesBConvertiblePreferredStockMember
2021-12-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
(State or other jurisdiction |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Address of principal executive offices) |
|
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
|
|
Results of Operations and Financial Condition. |
The disclosure set forth below under Item 7.01 (Regulation FD Disclosure) is incorporated by reference into this Item 2.02.
|
|
|
Regulation FD Disclosure. |
On June 7, 2022, Tenon Medical, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The disclosures under Item 2.02 and Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information provided herein shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits.
The following exhibits are being filed herewith:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title: Chief Executive Officer and President |
Grafico Azioni Tenon Medical (NASDAQ:TNON)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Tenon Medical (NASDAQ:TNON)
Storico
Da Dic 2023 a Dic 2024
